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1. Introduction 
Alzheimer’s disease (AD) is a chronic developing dementing disease characterized by 
coexistence of two types of lesions, the parenchymal amyloid deposits and the intraneuronal 
neurofibrillary tangles. Amyloid deposits are composed of amyloid-beta peptides that 
derive from sequential cleavages of its precursor named amyloid protein precursor (APP). 
Neurofibrillary tangles (NFT) results from intraneuronal aggregation of abnormally 
modified microtubule-associated Tau proteins. A synergistic relationship between the two 
lesions may trigger the progression of the disease. Thus, starting in the entorhinal cortex and 
slowly progressing through temporal, frontal, parietal and occipital cortex, the progression 
of NFT is well correlated with clinical expression of the disease. However, little is known 
about the mechanism underlying spatiotemporal propagation of these lesions ultimately 
leading to the disease. A growing number of studies suggest a prion-like diffusion of 
amyloid deposits and NFT, which could even be extrapolate to several other 
neurodegenerative diseases. In the present chapter, we will develop the current hypotheses 
regarding the molecular and cellular mechanisms driving the development and spreading of 
Alzheimer’s disease lesions involving multivesicular bodies. 
2. Alzheimer’s disease 
Alzheimer’s disease is a slow and progressive disease affecting the brain and characterized 
by the loss of superior cognitive functions leading to dementia and death. Two 
neuropathological brain lesions are found in the brain tissue and their presence is 
instrumental for providing a definite diagnosis of the disease, as firstly described by Alois 
Alzheimer (Alzheimer, 1911). Amyloid deposits are amorphous parenchymal deposits of ┚-
sheet ordered proteinaceous material. Amyloid deposition is observed with aging, in 
Alzheimer’s disease, Down’s syndrome, Dementia with Lewy bodies and vascular 
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dementia, all of which are aged-related neurodegenerative disorders. The major constituent 
of amyloid deposits is a small peptide of 39 to 43 amino acid residues, named A for 
amyloid-beta peptide (Glenner and Wong, 1984), which derives from multiple and 
sequential cleavages of a larger precursor, named amyloid precursor protein (APP). 
2.1 APP structure and metabolism 
The amyloid precursor protein APP is encoded by a single APP gene located on the long 
arm of chromosome 21 at position 21q11.2 (Kang et al., 1987; Goldgaber et al., 1987). The 
gene span more than 170kb and is constituted of 19 exons (Yoshikai et al., 1990). Alternative 
splicing generates seven isoforms but there is a single neuronal isoform in human adult 
brain that is composed of 695 amino acids (Konig et al., 1991). APP is a transmembrane 
protein with a large extra membrane domain, a transmembrane domain, and a short 
cytosolic tail composed of 59 amino acids (Fig. 1). The exact role of APP remains elusive but 
many functions have been proposed, for example APP was suggested to be instrumental to 
iron cellular homeostasis (Duce et al., 2010), to regulate intracellular transport, to be a cell 
surface receptor, and some fragments derived from the cleavage of APP are suggested to be 
neuroprotective or to promote axon outgrowth (Chasseigneaux et al., 2011) whereas others 
are related to an ancestral immunological mechanism of defense and would have 
antibacterial peptide property (Soscia et al., 2010). However, the full spectrum of APP 
functions remains to be elucidated. 
2.2 APP cleavage by secretases and amyloid production 
Proteolytic cleavage of APP brings into play sequential events involving first the liberation 
of its ectodomain either by - or -secretase activities. These cleavages generate carboxy-
terminal fragments remaining anchored to the plasma membrane and they shed 
extracellular soluble fragments, both of which are playing a role in axon outgrowth in vitro 
(Chasseigneux et al., 2011). The first cleavage to occur is mediated by -secretase. This 
cleavage generates a soluble APP fragment  (sAPP) and a carboxy-terminal  fragment 
composed of 83 amino acids (named C83 or CTF). This cleavage takes place within the 
sequence of A peptide thus precluding its formation. This pathway is therefore referred to 
as the non-amyloidogenic pathway. The -secretase activity is carried by metalloproteases 
called ADAMs (for A Disintegrin And Metalloprotease). Several ADAM proteases with an 
-secretase activity have been identified, including ADAM-17 or TACE (EC 3.4.24.86, 
peptidase family M12) (Buxbaum et al., 1998), ADAM-10 (EC 3.4.24.81, peptidase family 
M12) (Lammich et al., 1999 ; Lopez-Perez et al., 2001), and ADAM-9 (EC 3.4.24.-) (Hotoda et 
al., 2002; Koike et al., 1999). 
Alternatively to -secretase, APP can be processed by -secretase which can cleave at the 
first amino-terminal amino acid residue starting A peptide sequence or at position 11, 
referred to as ’-cleavage. This -cleavage generates a soluble fragment sAPP and a CTF 
comprised of 99 amino acids (C99 or CTF). This pathway is referred to as the 
amyloidogenic pathway. The protease responsible for both - and ’-cleavage has been 
identified as BACE-1 (for -site APP cleaving enzyme-1) (Memapsin 2, EC 3.4.23.46, 
peptidase family A1) (Hussain et al., 1999 ; Lin et al., 2000; Sinha et al., 1999 ; Vassar et al., 
1999 ; Yan et al., 1999). All APP-CTFs (CTF, ’ and ) can subsequently be cleaved at the 
juxtamembrane region by the -secretase. However, ectodomain cleavage of APP is 
mandatory to intramembrane -secretase proteolysis of APP-CTFs. 
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Fig. 1. Amyloid protein precursor structure and metabolism. (A) Schematic representation of APP 
structure. (B) APP processing by secretase activities. - and ┚-secretase activities cleave APP 
in its extracellular domain to release respectively a soluble fragment sAPP or sAPP┚ in the 
extracellular space and generate carboxy-terminal fragments CTF┙ or CTF┚. These CTFs can 
subsequently be processed by ┛-secretase to generate AICD and A┚ or p3. 
The APP intracellular domain (AICD) is released from both CTF and CTF. The -secretase 
cleavage of CTF represents the last step for A production. The -secretase is a 
multiprotein complex composed of at least four proteins which are necessary and sufficient 
to form an active enzymatic complex (Edbauer et al., 2003; Kimberly et al., 2003 ; Takasugi et 
al., 2003) which is composed of Presenilin (PS) (EC 3.4.23.-) (De Strooper et al., 1998 ; Zhang 
et al., 2000), Nicastrin (Esler et al., 2002; Yu et al., 2000), Aph-1 and Pen-2 (Bammens et al., 
2011; Francis et al., 2002 ; Goutte et al., 2002 ; Lee et al., 2002 ; Steiner et al., 2002; for review 
see Jorissen et al., 2010). APP is not the unique -secretase substrate. This aspartyl protease 
belongs to the family of intramembrane-cleaving proteases, which also comprises the signal-
peptide peptidases family of proteases (for review see Wolfe, 2010). Yet, more than 60 
substrates of the -secretase have been characterized including APP (Jorissen et al., 2010). 
Targeting the -secretase for drugs development that repress A┚ production is especially 
challenging due in part to the substrate-polyspecificity of this protease (For review see De 
Strooper et al., 2010). However, recent data has shown that Gleevec/Imatinib, a tyrosine 
kinase inhibitor anti-cancer drug, could repress A production without affecting -secretase 
cleavages of other substrates such as Notch (Netzer et al., 2003; He at al., 2010). Noteworthy, 
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A┚ production and release is repressed by Gleevec but AICD, which is released also from -
secretase cleavage of APP-CTFs, is not repressed. Thus, two products that are supposedly 
generated by a same -secretase protease can be oppositely regulated; one is reduced the 
other is increased. However, A┚ is generated only from CTF┚ whereas AICD can be released 
from several APP-CTFs as for other -secretase substrates. This mechanism is also observed 
with alkalizing drugs such as chloroquine, bafilomycin A1 and NH4Cl (Schrader-Fischer 
and Paganetti, 1996; Vingtdeux et al., 2007; Eisele et al., 2007), also referred to as 
lysomotropic drugs. Although, alkalizing drugs are known modifiers of intracellular and 
intravesicular pH, the molecular mechanism lowering A production without modifying 
other -secretase substrate cleavages remain elusive. A mechanism has recently been 
proposed for Imatinib/Gleevec. Gleevec may repress the regulating function of a novel 
modulator of -secretase protease activity named GSAP (Gamma-Secretase Activating 
Protein) (He et al., 2010). The substrate recognition of APP-CTFs is enhanced by GASP and 
consequently increases the production of A. Gleevec represses GASP association to the -
secretase complex leading to a selective lowering of A production but not AICD or other -
secretase substrates. 
2.3 Cell localization of secretase activities and lysosome contribution 
The ┙- and ┚-secretases are sheddases that release the extracellular domain of APP as well as 
several others type I transmembrane proteins. The cleavage and localization of enzyme 
activity is supposed to occur at the plasma membrane or in early endosomes. As for 
instance, BACE-1 resides within endosomes and APP endocytosis is a prerequisite for 
cleavage of APP by BACE1 and generation of A┚ (Ehehalt et al., 2003; Vassar et al., 1999; 
Walter et al., 2001). BACE-1 optimal protease activity necessitates an acidic pH and 
acidification of endosome occurs during the route of endosomes to fuse with lysosomes 
where BACE1 is degraded (Koh et al., 2005). Cleavage of APP-CTFs by -secretase can occur 
at several places in the cell (e.g. plasma membrane, endosomes…). Discrepancies exist 
regarding the cell localization of -secretase byproducts. Several APP metabolites including 
APP, APP-CTFs, A┚ and AICD have been shown to accumulate in multivesicular bodies 
following treatment of cells with alkalizing drugs (Verbeek et al. 2002; Vingtdeux et al., 
2007). Interestingly and similarly to Gleevec, these alkalizing drugs such as chloroquine, 
ammonium chloride, bafilomycin A1, block A┚ production without affecting AICD 
generation (Vingtdeux et al., 2007). AICD can be released outside the cell and also inside the 
cell, reach the nucleus (Goodger et al., 2009) where AICD may regulate gene expression 
(Pardossi-Piquard et al., 2005). Interestingly, intracellular AICD may be generated from 
APP-CTFs produced from -secretase (Belyaev et al., 2010). However, further investigation 
is needed to determine whether there is one or several AICD and what is the function of 
AICD. For instance, BACE1 cleavage of APP and AICD derived from CTF may contribute 
to learning, memory and neuronal plasticity (Ma et al., 2007). 
2.4 Neurofibrillary tangles and microtubule-associated Tau 
Neurofibrillary tangles are characterized by intraneuronal accumulation of fibrillar material 
named paired helical filaments. Abnormally modified Tau proteins are the major 
components of this filamentous material. Tau proteins belong to the family of microtubule-
associated proteins. A single gene, named MAPT located at position 17q21 encoded for 
several isoforms resulting from alternative splicing of exons 2, 3 and 10 in the human adult 
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brain. Thus, they are six isoforms, half of which contains the exon-10 encoding sequence, 
two-third are having the exon 2 whereas the exon 3 is found in one-third of Tau isoforms. In 
the human brain, Tau proteins constitute a family of six isoforms (six mRNAs) that range 
from 352 to 441 amino acids. Their molecular weight ranges from 45 to 65 kDa when 
resolved on polyacrylamide gel electrophoresis in presence of sodium dodecyl sulfate (SDS-
PAGE). The Tau isoforms differ from each other by the presence of either three (3R) or four 
repeat-regions (4R) in the carboxy-terminal (C-terminal) part of the molecule and the 
absence or presence of one or two inserts (29 or 58 amino acids) in the amino-terminal (N-
terminal) part (Goedert et al., 1989a; Goedert et al., 1989b; Andreadis et al., 1992). Each of 
these isoforms is likely to have particular physiological roles since they are differentially 
expressed during development. For instance, only one Tau isoform, characterized by 3R and 
no N-terminal inserts, is present during fetal stages, while the six isoforms (with one or two 
N-terminal inserts and 3 or 4R) are expressed during adulthood (Goedert and Jakes, 1990; 
Kosik et al., 1989). Exons 2 and 3 are alternatively spliced in the brain whereas included in 
muscle (Leroy et al., 2006). Thus, Tau isoforms are likely to have specific functions related to 
absence or presence of regions encoded by cassette exons 2, 3 and 10. Furthermore, the six 
Tau isoforms are not equally expressed in neurons. For example, Tau mRNAs containing 
exon 10 are not found in granular cells of the dentate gyrus (Goedert et al., 1989a). Thus, Tau 
isoforms are differentially distributed in neuronal subpopulations. 
Tau proteins bind microtubules through repetitive regions in their C-terminal part. These 
repetitive regions are the repeat domains (R1-R4) encoded by exons 9-12 (Lee et al., 1989). 
The three (3R) or four copies (4R) are made of a highly conserved 18-amino acid repeat 
(Goedert et al., 1989b, Himmler, 1989, Lee et al., 1988, Lee et al., 1989) separated from each 
other by less conserved 13- or 14-amino acid inter-repeat domains. Tau proteins are known 
to act as promoter of tubulin polymerization in vitro, and are involved in axonal transport 
(Brandt and Lee, 1993; Cleveland et al., 1977a; Weingarten et al., 1975). They have been 
shown to increase the rate of microtubule polymerization, and to inhibit the rate of 
depolymerization (Drechsel et al., 1992). The 18-amino acid repeats bind to microtubules 
through a flexible array of distributed weak sites (Butner and Kirschner, 1991, Lee et al., 
1989). It has been demonstrated that adult Tau isoforms with 4R (R1-R4) are more efficient 
at promoting microtubule assembly than the fetal isoform with 3R (R1, R3-R4) (Butner and 
Kirschner, 1991; Goedert and Jakes, 1990; Gustke et al., 1994). Interestingly, the most potent 
part to induce microtubule polymerization is the inter-region between repeats 1 and 2 (R1-
R2 inter-region) and more specifically peptide 274KVQIINKK281 within this sequence. This 
R1-R2 inter-region is unique to 4R Tau (since it occurs between exons 9 and 10), adult-
specific and responsible for differences in the binding affinities between 3R and 4R Tau 
(Goode and Feinstein, 1994). Recent evidence supports a role for the microtubule-binding 
domain in the modulation of the phosphorylation state of Tau proteins. A direct and 
competitive binding has been demonstrated between residues 224-236 (according to the 
numbering of the longest isoform) and microtubules on one hand, and residues 224-236 and 
protein phosphatase 2A (PP2A) on the other hand (Sontag et al., 1999). As a consequence, 
microtubules could inhibit PP2A activity by competing for binding to Tau at the 
microtubule-binding domains. The lysine residue 280 is crucial for microtubule-binding of 
4R Tau. This lysine is mutated in genetic form of FTDP-17 and promotes Tau aggregation in 
vitro and in vivo (Fischer et al., 2007; Eckermann et al., 2007). Much more recently, 
acetylation of Tau has been shown to regulate microtubule-binding of Tau (Min et al., 2010; 
Cohen et al., 2011). Histone acetyl transferase P300 or CREB-binding protein (CBP) and 
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deacetylase SIRT1 or HDAC6 likely regulate the acetylation of Tau (Min et al., 2010; Cohen et 
al., 2011). Moreover, Tau-acetylation is suggested to promote Tau aggregation and is 
observed in animal models, Alzheimer’s disease and brain tissues of patients with 
Tauopathies, at the exception of Pick’s disease where Pick bodies are negative for acetylated 
lys-280 as well as phosphorylation at ser-262 (Cohen et al., 2011; Sergeant et al., 1997; Probst 
et al., 1996). However, due to selective aggregation of 3R Tau in Pick’s disease (Delacourte et 
al., 1996; Sergeant et al., 1997), acetylation of 3R Tau on another lysine residue cannot be 
precluded. 
Besides its major microtubule-binding, -stabilizing, paralleled-ordering functions, Tau also 
has other functions. Tau proteins bind to spectrin and actin filaments (Carlier et al., 1984, 
Correas et al., 1990, Henriquez et al., 1995, Selden and Pollard, 1983). Through these 
interactions, Tau proteins may allow microtubules to interconnect with other cytoskeletal 
components such as neurofilaments (Miyata et al., 1986; Andreadis et al., 1995) and may 
restrict the flexibility of the microtubules (Matus, 1990). There is also evidence that Tau 
proteins interact with cytoplasmic organelles. Such interactions may allow for binding 
between microtubules and mitochondria (Jung et al., 1993). The Tau N-terminal projection 
domain also permits interactions with neural plasma membrane (Brandt et al., 1995). Thus, 
Tau may act as a mediator between microtubules and plasma membrane. This interaction 
has been defined as involving a binding between the proline-rich sequence in the N-
terminal part of Tau proteins and the SH3 domains of Src-family non-receptor tyrosine 
kinases, such as Fyn. Studies have determined that human Tau Tyr18 and Tyr29 are 
phosphorylated by the Src family tyrosine kinase Fyn (Lee et al., 2004; Williamson et al., 
2002). The same proline-rich region of Tau proteins is likely involved in the interaction with 
phospholipase C-┛ (PLC-┛) isozymes (Jenkins and Johnson, 1998; Hwang et al., 1996). 
Hwang and colleagues have demonstrated in vitro that Tau proteins complex specifically 
with the SH3 domain of PLC-┛, and enhance its activity in the presence of unsaturated fatty 
acids such as arachidonic acid. These results suggest that in cells that express Tau proteins, 
receptors coupled to cytosolic phospholipase A2 may activate PLC-┛ indirectly, in the 
absence of the usual tyrosine phosphorylation, through the hydrolysis of 
phosphatidylcholine to generate arachidonic acid (Jenkins and Johnson, 1998; Hwang et al., 
1996). Altogether, these data indicate that Tau proteins may also play a role in the signal 
transduction pathway involving PLC-┛ (for review see Rhee, 2001). In line with this idea, 
recent data demonstrate that Tau is necessary for glutamatergic signaling (Ittner et al., 2010). 
2.5 The cortical brain spreading of neurofibrillary degeneration 
With aging, neurofibrillary tangles are affecting the entorhinal cortex followed by the 
hippocampal formation. At this stage, no clear clinical symptoms are associated with the 
presence of these lesions and they are therefore considered as an aging-associated 
phenomenon. But this remains an open debate. Indeed, neuropathological as well as 
biochemical approaches show that Tau pathology of Alzheimer’s disease spreads 
progressively, invariably, hierarchically, from the transentorhinal cortex to the whole 
neocortex, along cortico-cortical connections. The brain regions that are sequentially affected 
explain well the successive types of cognitive impairments that characterize the disease: 
amnesia following the entorhinal and hippocampal degeneration; aphasia, apraxia and 
agnosia with the involvement of the neocortex. Of course, amyloid and Tau pathology are 
present before the clinical symptoms, because neuronal plasticity is able to compensate at 
the first AD stages. Our studies show that Tau pathology is already distributed in the 
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hippocampal formation and the temporal cortex at the “pre-clinical” stage of AD 
(Delacourte et al., 1999, 2002). 
PHF-Tau pathology, visualized as a triplet of abnormal Tau proteins, was systematically 
present in variable amounts in the entorhinal and hippocampal regions of non-demented 
patients aged over 75 years. When Tau pathology was found in other brain areas, it was 
always along a stereotyped, sequential, hierarchical pathway. The progression was 
categorized into 10 stages according to the brain regions affected: transentorhinal cortex 
(S1), entorhinal (S2), hippocampus (S3), anterior temporal cortex (S4), inferior temporal 
cortex (S5), mid temporal cortex (S6), polymodal association areas (prefrontal, parietal 
inferior, temporal superior) (S7), unimodal areas (S8), primary motor (S9a) or sensory (S9b, 
S9c) areas, and all neocortical areas (S10). Up to stage 6, the disease could be asymptomatic. 
In all cases of our study, stage 7 individuals with two polymodal association areas affected 
by Tau pathology were cognitively impaired. Since the neuropathological observation of 
this stereotype cortical brain progression of Tau pathology (Braak and Braak, 1991; 
Duyckaerts et al., 1997) is the question of how does neurofibrillary degeneration is selective 
toward neuronal subpopulations of cortical brain layers III and V (Hof et al., 1990) and 
progressively propagates through brain structures. 
3. Multivesicular bodies and exosomes 
3.1 Multivesicular bodies 
During endocytosis, some of the extracellular components, such as viruses, ligands or 
diffusible factors and, part of the plasma membrane proteins are internalized and are either 
recycled to the cell surface via early endosomes and recycling endosomes or will be address 
through a set of vesicular compartments: early endosomes, late endosomes and finally 
delivered to lysosomes for degradation (for review see Gruenberg, 2009). Late endosomes 
are also known as multivesicular endosomes or multivesicular bodies (MVBs) (Gruenberg 
and Stenmark, 2004; Raposo and Marks, 2007) and are prerequisite before degradation of 
internalized material by fusion with lysosomes. Multivesicular bodies are large vesicles of 
several hundred nanometers that are characterized by numerous smaller intraluminal 
vesicles (ILVs) formed by the inward budding of the endosome limiting membrane. The 
formation of these intraluminal vesicles requires sequential steps and the contribution of 
complex multi molecular machinery named ESCRT for Endosomal Sorting Complex 
Required for Transport. The ESCRT machinery is composed of four ESCRT complexes (0, I, 
II and III) acting sequentially to sort cargo and to form a coated subdomain on endosomes 
that forms the ILVs (Fig. 2). The Vps27/Hrs-Hse1/STAM complex (ESCRT-0) is first 
recruited to the endosomes by binding PI(3)P and ubiquitinated cargos. ESCRT-0 then 
recruits ESCRT-I (composed of Tsg101/Vps23-Vps28-Vps37) to the membrane, where 
ESCRT-I interacts with ubiquitinated cargos via its Vps23 subunit. Then, ESCRT-I recruits 
ESCRT-II complex (composed of Vps22/Eap30-Vps25/Eap25-Vps36/Eap45), which in turn 
initiates the oligomerization of ESCRT-III complex (composed of Vps2/CHMP2-
Vps20/CHMP6-Vps24/CHMP3-Snf7/Vps32/CHMP4). Finally, ESCRT-III recruits 
supplementary factors like Bro1 and Vsp4 AAA ATPase. Bro1 will recruit a deubiquitination 
enzyme whereas Vps4 AAA ATPase will work to break apart ESCRT-III and other ESCRT 
complexes, resulting in their dissociation from the membrane. Evidences for alternative 
pathways for cargos sorting into MVBs are emerging, which are independent of the ESCRT 
machinery but seems to depend on lipid composition of raft-based micro domains. Proper 
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cholesterol levels in late endosomes generated by ORPs (oxysterol-binding protein-related 
proteins) are required for normal MVBs formation and MVB-mediated membrane protein 
degradation (Kobuna et al., 2010).  
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Fig. 2. Model for the ubiquitin-dependent sorting of proteins by the ESCRT machinery. The 
different ESCRT complexes act sequentially for the recognition and sorting of ubiquitinated 
transmembrane proteins into the internal vesicles of multivesicular bodies. 
The phospholipid LBPA (lysobisphosphatidic acid) possessed the capacity to drive the 
formation of membrane invaginations within acidic liposomes. Alix controls this 
invagination process in vitro and the organization of LBPA-containing endosomes in vivo 
(Matsuo et al., 2004). These micro domains also contain high concentrations of sphingolipids 
from which ceramide are formed. Ceramide induced the coalescence of small microdomains 
into larger domains, which promotes domain-induced budding. In addition ceramide cone-
shapped structure might induce spontaneous negative curvature by creating an area 
difference between the membrane leaflets (Trajkovic et al., 2008). Ubiquitination (Ub) is the 
main sorting signal for cargo entry into the vesicles that bud from the limiting membrane 
into the lumen of endosomes during the biogenesis of MVBs. A single Ub is sufficient to 
direct ILV targeting. Ub is recognized by an expanding cohort of endosomal proteins, which 
may act as Ub-sorting receptors responsible for binding and directing cargo toward ILVs 
like some ESCRT subunits, including Vps27/Hrs, Vps23/Tsg101 and Vps36/Eap45 (For 
review see: Piper and Katzmann, 2007). Many integral membrane proteins targeted for 
lysosomal degradation are ubiquitinated; however, non-ubiquitin sorting signals have also 
been described. Much less is known about non-Ub signals that sort proteins to ILVs; 
proteins which have been described to enter ILVs in an Ub-independent manner include 
Pmel17/Silver (Berson, 2003), TfR (Geminard, 2004), Nedd4 (Morita and Sundquist, 2004), 
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sna3 (McNatt, 2007; Oestreich 2007). Two motifs ‘NTR’ and ‘PKD’ located on the 
extracellular part of Pmel17 are responsible for its targeting into the internal vesicles of 
MVBs (Theos et al., 2006) and COP9 signalosome (CSN)-associated protein CSN5 is involved 
in protein sorting into ILVs since siRNA of CSN5 causes a significant increase in both 
ubiquitinated and non-ubiquitinated proteins detected in exosomes (Liu et al., 2009). 
Genetic also supports the importance of functional MVB in neurological disease and 
frontotemporal dementia. Thus, the gene encoding the ESCRT-III subunit CHMP2B was 
found to be mutated in a form of frontotemporal dementia (Skibinski et al., 2005) and 
amyotrophic lateral sclerosis (Cox et al., 2010) suggesting that functional MVBs are required 
to prevent accumulation of abnormal proteins that can disrupt neural function and 
ultimately lead to neurodegeneration (Filimonenko et al., 2007). Mutations in CHMP2B were 
first described in Danish and Belgian families but remain rare (Ghanim et al., 2010). 
Mutations are supposed to lead to C-terminal truncation of CHMP2B. Brain tissue 
examination of patient with CHMP2B mutation showed enlarged vacuoles stained with a 
mannose-6-phosphate receptor antibody. The truncated protein impairs the fusion of 
endosome with lysosomes without obvious modification of protein sorting to MVB (Urwin 
et al., 2010). Staining of tissue from Alzheimer disease patients with CHMP2B showed an 
accumulation of the protein in vesicular structures resembling GranuloVacuolar 
Degeneration (Yamazaki et al., 2010; Funk et al., 2011) suggestive of defective autophagic 
and endocytic pathways in Alzheimer disease. Thus, restoring or enhancing the lysosomal 
degradation and rates of autophagic protein turnover in a transgenic animal model of 
amyloid deposition can rescue the phenotype and decrease the amyloid burden (Yang et al, 
2011). Together, a defective function of the endocytic pathway including MVB, autophagy 
and lysosome may certainly contribute to the development of Alzheimer disease. 
3.2 Exosomes 
Alternatively to their fusion with lysosomes for degradation of their contents, MVBs have been 
described to fuse with the plasma membrane and release their content in the extracellular space, 
the ILVs contained in the MVBs when released are known as exosomes. Exosomes have a size 
ranging from 40 to 100 nm and can be secreted by many cell types including neuronal cells 
(Faure J et al., 2006; Rajendran et al., 2006; Vingtdeux et al., 2007; Lachenal et al., 2010). Exosomes 
are isolated from the media of cultured cells. However, purification of exosomes is not trivial 
since membrane fragments or cell debris can easily contaminate exosome preparation. Due to 
their small size, exosomes are obtained after filtration on 0.22 µm filters and by a series of 
centrifugation and sucrose gradient (Raposo et al., 1996; Wubbolts et al., 2003; Faure et al., 2006; 
For review see Olver and Vidal, 2007). Further immunoisolation can be used (Wubbolts et al., 
2003). Several parameters should be evaluated to ascertain the purity of exosomes preparation. 
The first and likely most important characteristic is the observation of exosomes by 
transmission electron microscopy. Several proteins are also common to exosomes and described 
in exosomes preparation that originate from different sources (For review Vella et al., 2008). 
Interestingly, several tetraspanins proteins are enriched in exosomes and may contribute to 
exosomes formation (De Gassart et al., 2004; Wubbolts et al., 2003). Tetraspanins are a growing 
family of transmembrane proteins with pleiotropic functions found associated with lipid-raft 
micro domains (for review Hemler et al., 2005). Interestingly, tetraspanins CD81 and CD9, 
which are found in exosomes derived from B-cells (Wubblots et al., 2003), are co-purified with 
the ┛-secretase interactome. Absence of those tetraspanins induces a partial disruption of ┛-
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secretase activity or reduces ┛-secretase substrate interaction (Wakabayashi et al., 2009). 
Although detailed molecular mechanisms remain unknown, together those results further 
support the idea that MVB and most possibly exosomes are important cellular compartments 
for APP metabolism regulation and that several ┛-secretase regulators may act at this level. 
Little is known about the requirements and regulation of MVBs fusion with the plasma 
membrane and the release of exosomes outside cells. Recently, in primary neuronal 
culture cell, release of exosomes by neurons was shown to be regulated by glutamatergic 
signaling (Lachenal et al., 2010). Calcium ionophores stimulate exosomes release in some 
cell types suggesting that intracellular calcium levels also play a role in plasma membrane 
fusions event. The Rab family of GTPase proteins seems to be required for exosomes 
release. Rab11, a well-known regulator of endosomal recycling, has been linked to the 
control of exosomes release in K562a cells (Savina et al., 2005). Silencing of five other Rab 
proteins, Rab2b, Rab9a, Rab5a, Rab27a and Rab27b inhibited exosomes secretion. Rab27a 
and Rab27b function in MVBs docking to the plasma membrane (Ostrowski et al., 2010). 
Inhibition of Rab35 function leads to intracellular accumulation of endosomal vesicles and 
impairs exosomes secretion possibly by controlling the docking/tethering of endocytic 
vesicles with the plasma membrane (Hsu et al., 2010). MVBs fate can be affected by 
macroautophagy (hereafter referred to as autophagy). During autophagy, parts of the 
cytoplasm and organelles are encapsulated in double-membrane vacuoles called 
autophagosomes, which eventually fuse with lysosomes for degradation (for review see 
Levine et al., 2011). Under conditions that stimulate autophagy, MVBs are diverted to 
autophagic pathway with subsequent inhibition in exosomes secretion (Fader et al., 2008). 
With regards to Tau, the autophagy-lysosomal pathway contributes to the degradation of 
Tau (Wang et al., 2009). 
How exosomes are processed in recipient cells is not yet fully understood. Exosomes are 
able to be endocytosed into the endosomal system of recipient cells. Once internalized, 
exosomes could fuse with the limiting membrane of endosomes to deliver their cytoplasmic 
content into the host cell cytoplasm. It is also possible that exosomes could directly fuse with 
the plasma membrane. Although their exact function remains to be discovered, within the 
extracellular space and in biological fluids such as urine or serum, exosomes have been 
proposed to participate in different physiological and/or pathological processes such as 
neurodegenerative diseases (for review see Vella et al., 2008). They could be responsible not 
only for protein and lipids exchange between cells, but also for mRNA and microRNAs 
exchange (Valadi et al., 2007). Exosome release and content may be regulated by cellular 
stress. Thus DNA damage and activation of p53 induce the expression of protein that will be 
included inside exosomes (Yu et al., 2006). Exosomes may mediate a signal of cellular 
damage or stress. In the central nervous system, exosomes are proposed to constitute an 
intercellular communication system (for review see Mathivanan et al., 2011). AICD and 
several APP metabolites are found in exosomes derived from primary neuronal cultured 
cells (Vingtdeux et al., 2007) (Fig. 3). L1 CAM that is also processed by -secretase (Riedle et 
al., 2009) is recovered in exosomes (Lachenal et al., 2011). Although speculative, if several 
intracellular domains of proteins processed by -secretase are internalized and secreted 
within exosomes, the fusion of those exosomes with surrounding cells may regulate gene 
expression by those intracellular domains and therefore constitute a cell communication 
system. 
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Fig. 3. APP and its metabolites are present in multivesicular bodies and exosomes. APP and APP-
CTFs are internalized and directed into the internal vesicles of multivesicular bodies (MVB). 
At this point APP and its metabolites can either be degraded after the fusion of MVB with 
lysosomes or can be released in the extracellular space in association with exosomes 
consecutively to the fusion of MVB with the plasma membrane. 
4. Prion-like propagation of amyloid and Tau pathology 
Besides being a potential system of intercellular communication, exosomes are also known 
to be instrumental to the dissemination of pathogens, whether those are viruses or 
proteinaceous pathogens. The first pathological protein described associated with exosomes 
was the prion protein (PrP) (Fevrier et al., 2004; Alais et al., 2008). Prions diseases are fatal 
neurodegenerative disorders. They are associated with the conversion of the cellular prion 
protein (PrPc) into the scrapie PrP (PrPSc), an abnormal conformational state that tends to 
form amyloid deposits in brain tissue leading to dementia. Into its misfolded conformation 
the PrPSc is thought to be infectious (For review see Aguzzi and Rajendran, 2009). Recent 
findings revealed an unexpected role for exosomes in vehiculation of prions: exosomes from 
prion-infected neuronal cells have been demonstrated to be efficient initiators of prion 
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propagation in uninfected recipient cells and, more importantly, to produce prion disease 
when inoculated into mice. 
4.1 Amyloid propagation 
Exosomal release instead of lysosomal processing might be of advantage to cells that have 
poor degradative capacities. In the context of AD, exosomes secretion could be a way to 
dispose of unwanted proteins. Indeed, maturation of autophagolysosomes and their 
retrograde transport are impeded in AD. The underlying mechanism behind the hypothesis 
that neurodegeneration in AD is triggered by proteins spread, cell-to-cell, throughout brain 
areas could be the shipping of toxic agents such as A┚ or Tau by exosomes. What at the 
beginning would be beneficial (to bypass a degradation system which is overwhelmed) 
could become the reason why there is propagation of the disease thorough the brain. A┚ 
peptides are released by cells in association with exosomes (Rajendra et al., 2006) and 
interestingly, exosomal proteins such as Alix and flotillin-1 were observed around neuritic 
plaques, a lesion found in brains from AD patients (Rajendran et al., 2006) suggesting that 
exosomes-associated A┚ could be involved in plaque formation. MVBs are an intracellular 
compartment where internalized A┚ can grow into fibrils thereby MVBs may also contribute 
to amyloid plaque formation (Friedrich et al., 2010). Overall these results suggest that 
exosomes could play a role in the pathogenesis of AD.  
4.2 Tau pathology propagation 
The stereotype propagation scheme of neurofibrillary degeneration in AD is evidenced by 
neuropathological examination as well as biochemical analyses but until recently, 
hypotheses and experiments trying to address this question remained elusive. 
Neurofibrillary degeneration is following cortico-cortical connections therefore suggesting a 
loss of neurotrophic factor or a diffusible factor responsible for a cascade of molecular 
events leading to Tau aggregation and neuronal death. However, what is this propagating 
factor? What if Tau itself wouldn’t be the “missing link”? Thus, recent data suggest that 
neurofibrillary degeneration cortical spreading could follow a transmissible prion-like 
process. In fact, aggregates of PHF-Tau were purified from a transgenic mice model of 
neurofibrillary degeneration. Intracranial injection of this preparation was done in a 
different mouse model, which overexpresses human Tau protein but does not display Tau 
pathology. Following the injection, development of a Tau pathology was observed. This 
pathology progressed from the injection site to neighboring brain structures, suggestive of a 
propagating mechanism (Clavaguera et al., 2010). However, results show that PHF-Tau are 
sufficient to promote the transformation of normal human Tau into “pathological Tau” 
leading to the formation of neurofibrillary degeneration, the prototypical neuropathological 
lesion of Alzheimer disease. However, how an extracellular transmissible agent could reach 
the intracellular compartment to transform the normal protein remains an open question. 
Very recently, Frost and collaborators have shown using a cell-based system that 
extracellular Tau aggregates are internalized inside cells and promote the mis-folding and 
fibrillization of Tau (Frost et al., 2009). Internalization of preformed Tau fibrils is facilitated 
by the use of a lipid-based protein delivery system (BioPorter®) and is likely mediated by 
endocytosis (Guo et al., 2011). Moreover, in addition to transmissibility of Tau-fibril 
conformation, the internalized preformed fibrils reduce microtubule-stabilization 
suggesting a loss-of-function of normal Tau in infected cells. Although, the mechanisms of 
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Tau fibrils diffusion remain elusive in vitro and in vivo arguments strongly support the 
notion of prion-like transmissibility of Tau-PHF in Alzheimer’s disease and possibly in other 
Tauopathies. There are some evidences suggesting that Tau may be secreted and secretion 
of Tau may differ depending of Tau isoform. Thus, Tau isoforms with exon 2 encoding 
sequence are likely not secreted and this exon 2 sequence is therefore suggested to repress 
Tau secretion (Kim et al., 2010). However, it is not known how Tau is secreted, exosomes? 
Preliminary study suggests that Tau is not in the exosomes derived from primary embryonic 
neuronal culture cells (Fauré et al., 2006). Further work is therefore needed to determine how 
Tau is secreted and by which cell-based mechanism. A good example of such a dilemma is 
fibroblast growth factor 2 that is a secreted growth factor without any signal peptide and 
that is also found in cell nucleus following its interaction with its cognate receptors 
(Meunier et al., 2009). Tau is likely secreted and is also located into the nucleus following 
stress conditions (Sultan et al., 2011). Tau secretion, as for Tau nuclear localization, may 
depend upon yet undefined conditions and therefore, contributions of MVB-exosomes 
pathways or autophagy-lysosomal pathways (Wang et al., 2009) remain completely open. 
Recent data strongly suggest that both pathways are possibly interconnected (Sahu et al., 
2010). With regards to Tau, the degradation systems may bring insights for the potential 
routing of Tau to MVB-exosomes or autophagy lysosome pathway. In NFT or more 
generally in aggregates, Tau is found ubiquitinated, thus suggesting that Tau may be 
processed by the proteasome (David et al., 2002). Ubiquitin-independent degradation 
system, such as the caspase or calpain cleavage of Tau have also been described (Berry et al., 
2003; Carrettiero et al., 2009; Delobel et al., 2005; Ding et al., 2006; Ferreira et al., 2011) The 
autophagy-lysosomal pathway contributes to the degradation of Tau via the chaperone-
mediated autophagy (CMA) (Wang et al., 2009; for review see Wang et al., 2010). The CMA is 
a lysosome-mediated degradation system of cytosolic protein (for review see Arias et al., 
2010). This system implies the recognition of substrates by a complex of chaperones and 
translocation of substrates inside lysosomes for further degradation. The CMA malfunction 
has been connected to the development of several neurodegenerative diseases including 
Parkinson disease and Alzheimer Disease (Arias et al., 2010). Although speculative and 
purely hypothetic, through the use of CMA, aggregates of proteins or even oligomers could 
reach the lysosome and due to their low sensitivity to degradation (e.g. Tau aggregates), the 
fusion of lysosome with other vesicular structures such as MVB could finally lead to the 
release of aggregates outside the cell and contribute to their propagation following neuronal 
connections. Alternatively, proteins such as Tau would normally be addressed to lysosome 
by the CMA system but a defective lysosome could be the place where oligomers are 
generated and thereafter route to MVB/exosome pathway. However, further work is 
definitely needed to get insights into these mechanisms. 
5. How to explain the selective patterns of neurodegeneration in 
Tauopathies? 
Conceptually, how could we imagine that prion-like spreading of misfolded proteins could 
reproducibly cause selective patterns of neurodegeneration and skipping nearby "less 
vulnerable" neuronal targets. That’s certainly a major fundamental question to address, 
which to date remains with no clear answer even in prion disease. Why is the brain affected 
in prion diseases and no other organs? Why in this scheme of spatiotemporal spreading and 
propagation of lesions in Alzheimer disease and other tauopathies only selective neuronal 
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subpopulations are affected. As for instance, affected neurons in Alzheimer disease 
essentially belong to the cholinergic system. One possibility would be that selectivity of 
propagation could follow neuronal circuitry through synaptic transmission. This is possible 
if exosomes are preferentially release at the synaptic junction, as suggested by Smalheiser 
(2007). They are strong evidences that exosomes are produced and secreted by neurons 
(Lachenal et al., 2011). However, the demonstration derives from in vitro experiments using 
primary neuronal embryonic culture cells. Study of exosomes in tissue yet remains highly 
challenging. Consequently, little if not nothing is known about the cell localization of 
exosomes release and their propensity of diffusion in vivo. They are therefore other 
possibilities, such as the tunneling nanotubes (for review see Goedert et al., 2010). Tunneling 
nanotubes are fine membrane channels that have recently been described in mammalian 
cells for communication between cells but also for cell-to-cell propagation of misfolded 
prion proteins (for review see Gerdes et al., 2007; Gousset et al., 2009). These tunneling 
nanotubes could also propagate other transmissible misfolded proteins but the question of 
selectivity of transmission remains however open. Coming back to exosomes and now 
considering that exosomes release and secretion is controlled and localized to pre- or post-
synaptic locations then several hypotheses can be postulated. In both pre- and post-synaptic 
situations propagation through exosomes would be closely dependent upon neuronal 
connections, as far as the diffusion of exosomes is following a paracrine or “juxtacrine” rule 
of diffusion (Mathivanan et al., 2010). Thus, only interconnected neurons would disseminate 
toxic species via exosomes. We can also imagine that exosomes originating from different 
type of neurons (e.g. cholinergic, GABAergic, glutamatergic…) and may contain specific 
membrane associated biomarkers. Intercellular communication mediated by exosomes may 
result from passive fusion of exosome membrane with the plasma membrane of the targeted 
cell or may use a ligand receptor system. In line with the latter system, the selectivity of 
intercellular communication could result from specific interaction between ligand and 
receptor. They are several examples that could illustrate a selectivity of propagation of 
exosomes using this ligand receptor selectivity. For instance, protocadherin is a cluster of 52 
cadherin-like genes with a singular organization. The amino-terminal region of 
protocadherins is encoded by three sets of separate exons arranged in three clusters (alpha, 
beta and gamma). N-terminal encoding exons are spliced with one of three carboxy-terminal 
encoding exons. Alternative splicing generates an extraordinary diversity of protocadherin 
isoforms suggested to confer selective and specific intermolecular membrane-associated 
protein interactions (Wu et al., 2000; Wang et al., 2002). The second example is DSCAM, the 
Drosophila homolog of human Down syndrome cell adhesion molecule that belongs to the 
axonal guidance receptor family. Alternative splicing of DSCAM can generate as many as 
38016 mRNA isoforms and therefore lead to expression of huge protein diversity 
(Schmucker et al., 2000). More interestingly, one DSCAM protein isoform binds exactly to 
the same isoform but not a slightly different one, making the binding of DSCAM isoforms 
very stringent (Wojtowicz et al., 2004). As for DSCAM, the selectivity of transmission pattern 
could be mediated following an axonal guidance-like system. In a very simplified view, 
axonal guidance is driven by equilibrium between attractive and repulsive signals through 
specific signaling pathways, allowing axonal growth and connection to its specific neuronal 
target (for review see Bashaw and Klein, 2011). Thus exosomes release from one type of cell 
will be attracted by its target cell and repulsed by surrounding cells. Altogether, examples 
provide could contribute to neuronal communication and propagation of misfolded proteins 
along specific identified neuronal circuitries. Although, all these hypotheses could be 
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envisioned a better knowledge of the metabolism of exosomes in vitro and in vivo is 
necessary to address this problematic. 
6. Conclusion 
Among pathophysiological mechanisms of neurodegenerative diseases leading to intra or 
extracellular protein aggregates, a consensual mechanism support a common mechanism of 
prion-like propagation of mis-folded proteins. However, when this mechanism implies the 
propagation from cell-to-cell, cellular pathways incriminate remains poorly understood. A 
growing body of evidences suggests that the endocytic – multivesicular and exosomes 
pathways may be instrumental to this process. Much is known about the routing of proteins 
through those recycling or degradative pathway but much less is known about the 
contribution of those systems to the development of neurodegenerative diseases. However, 
this MBV-exosome system can be diverted from its physiological function as for instance to 
produce human immunodeficiency viral particles (Nguyen et al., 2003; for review see Gould 
et al., 2003). Following this hypothesis, the autophagy-lysosome and/or MVB-exosome 
pathways could also be diverted to deliver and propagate toxic oligomers or aggregates in 
neurodegenerative disease such as Alzheimer’s disease. Blocking intracellular inclusion of 
those toxic species to this secretory pathway could also represent a potential therapeutic 
approach of neurodegenerative diseases such as Amyloidopathies, Tauopathies, 
Synucleopathies, all of which are sharing a “prion-like” propagation of toxic mis-folded 
proteins. 
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Acknowledged experts provide highly informative yet critical reviews of the factors that most likely contribute to
Alzheimer's, including genetics, metabolic deficiencies, oxidative stress, and possibly environmental
exposures. Evidence that Alzheimer's resembles a brain form of diabetes is discussed from different
perspectives, ranging from disease mechanisms to therapeutics. This book is further energized by discussions
of how neurotransmitter deficits, neuro-inflammation, and oxidative stress impair neuronal plasticity and
contribute to Alzheimer's neurodegeneration. The diversity of topics presented in just the right depth will
interest clinicians and researchers alike. This book inspires confidence that effective treatments could be
developed based upon the expanding list of potential therapeutic targets.
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